April 26, 2016: Here are four stocks trading with relatively heavy volume among 14 equities making new 52-week lows in Tuesday’s session. NYSE advancing stocks led decliners by about 3 to 1…
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Broadcom, Caterpillar, Sirius XM, Newmont, Palo Alto, Perrigo, Sarepta and Xerox.
Although the markets have made their comeback, some stocks are still slowing that recovery and punishing their shareholders. Last week that included Netflix and Sarepta Therapeutics.
Sarepta Therapeutics shares got crushed on Thursday and then exploded on Friday following the FDA view on its Duchenne muscular dystrophy treatment.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Wednesday morning include ArcelorMittal, Boeing, Intel, Johnson & Johnson, Schlumberger, Yahoo and Vivint Solar.
After a week when the indexes finally fought their way back to even for 2016, one probably would think that insiders would be selling the huge rally. Just the opposite happened.
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Stocks tanked on Friday but were indicated sharply higher on Tuesday after the three-day weekend and after China’s gross domestic product met expectations. While investors may feel that every rally has been…
While these were not the five biggest absolute losers of the week, of the active stocks, these all issued news or had news that took place and pushed the stocks down.
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
A new Jefferies research report focuses on some biotech and specialty pharmaceutical stocks that have had some headline and clinical issues muddy the waters.
24/7 Wall St. examines Valeant Pharmaceuticals and other biotech stocks with incredible gains or losses over the course of the past week.
A new Jefferies research report highlights four top companies that could be looking at catalysts that in the very near term could have a huge impact on the stocks.
We combed through the Merrill Lynch database and found three biotech companies that at one time or another, when they were much higher than they are now, had analysts going crazy.
Lee Jackson Sarepta announced a public offering of more than 3 million shares of its common stock at a price to the public of $39.00 per share, with a value of up to more…
Chris Lange 
